Microbix Biosystems (TSX:MBX) has made its first full-scale shipment of antigen, produced using its new bioreactor manufacturing process, following customer validation.
Bioreactors offer the prospect for better process control, greater production capacity in the same facility space and reduced per-unit costs.
Moving to bioreactor processes also involves validation of the resulting product by customers. The completion of internal processes and external validation has resulted in the first full-scale shipment of antigen made by bioreactors.
“Adoption of bioreactors will enable Microbix to better meet our customers’ needs for increasing quantities of high quality antigens on a cost-effective basis,” Phil Casselli, SVP of sales and business development, said in a statement.
“We are excited about our bioreactor capability becoming fully-commercial and intend to quickly add to our bioreactor capacity,” he added.
Cameron Groome, president and CEO, said the company’s move to bioreactor production required considerable time, work and capital, but was needed. “Our adoption of state-of-the-art technology positions Microbix to accelerate sales growth and further build on its reputation as a supplier of biologicals critical to the diagnostics industry and important to public health.”
